Drugs giant AstraZeneca has had a bad run of late so news that a US District Court has ruled that the formulation patent protecting its SEROQUEL XR blockbuster drug is valid will be most welcome.
The US District Court for the District of New Jersey also ruled that generic drugs makers Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals, Torrent Pharma, Mylan Pharmaceuticals and Mylan have all infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.
The court decision. which only affects the US markets, follows a decision made in the UK on 22nd March 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on 7th March 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
JH
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
